Quantcast

The PAWS Pet Company, Inc. acquires Mesa Pharmacy. 2014 gross revenues are expected to approach $100,000,000.

January 9, 2014

PALO ALTO, CA, Jan. 9, 2014 /PRNewswire/ – The PAWS Pet Company, Inc.
(OTCQB:PAWS), is pleased to announce that on December 31, 2013, PAWS
closed the acquisition of Mesa Pharmacy Inc. (“Mesa”).

Preliminary unaudited gross revenue numbers for fiscal year 2013 appear
to have exceeded $15,000,000, almost half of which occurred in the
fourth quarter of 2013. While December is generally a slow month for
Mesa, preliminary results show Mesa shipped close to $2,000,000 in
prescriptions during December. Expected sales for January are expected
to exceed November’s sales of more than $3,000,000. Mesa already has
$2,000,000 in in prescription orders in hand which are expected to be
shipped during the week of January 13, 2014.

Furthermore, Mesa has obtained financing against a portion of its 2013
Accounts Receivables received more $1,200,000 on January 3, 2014 for
marketing expenses and working capital.

Several action items remain following the closing which including
changing the name of the Company to “Praxsyn Corporation”, among
others.

About The PAWS Pet Company, Inc.

The PAWS Pet Company, Inc. is undergoing a transition from the pet space
to the pharmaceutical space. This exciting transition strategy has been
developed to take advantage of the changes underway in traditional
medical services. PAWS believes that great opportunities exist in
pharmaceuticals and how they are delivered to the public.

About Mesa Pharmacy, Inc.

Mesa focuses on providing custom compounded non-narcotic, transdermal
topical pain medications that are marketed to industrial health
physicians and clinics. Mesa compounds a series of topical ointments,
in different strengths, that provide the pain relief doctors seek and
that are neither addictive, nor habit forming. As a result, physicians
and insurers need not worry about treating an injured worker and
winding up having to treat that worker’s potential addiction to pain
killing narcotics.

For more information on The PAWS Pet Company go to: www.thepawspetcompany.com

Forward-Looking Statements

Certain statements made in this press release are forward-looking in
nature (within the meaning of the Private Securities Litigation Reform
Act of 1995) and, accordingly, are subject to risks and uncertainties.
The actual results may differ materially from those described or
contemplated and consequently, you should not rely on these
forward-looking statements as predictions of future events. Certain of
these risks and uncertainties are discussed in the reports we filed
with the SEC.

SOURCE The PAWS Pet Company, Inc.


Source: PR Newswire



comments powered by Disqus